Entrada, Vertex licensing deal on muscle disorder program closes after US antitrust clearance
fotostorm


Entrada Therapeutics (NASDAQ:TRDA) closed a licensing agreement with Vertex Pharmaceuticals (NASDAQ:VRTX) targeting muscular disorder myotonic dystrophy type 1 (DM1) after the waiting period under the U.S. antitrust law expired.
The companies had signed a collaboration agreement in December 2022. Entrada will receive $224M upfront, and $26M as an equity investment from Vertex at $16.26 per share.

Entrada is eligible to receive up to $485M in certain research, development, regulatory and commercial milestones, and royalties on net sales.
The agreement includes a four-year global research collaboration under which Entrada will continue to advance and receive payments for certain research activities related to ENTR-701, and an additional DM1-related research activities.
Vertex will be responsible for global development, manufacturing and commercialization of ENTR-701 and any additional programs arising from Entrada's DM1 research efforts.
Entrada said its cash runway is extended into H2 of 2025.
VRTX +0.26% to 294.10 premarket Feb. 9